The past 5 years have seen dramatic growth in the evidence supporting vast IBD heterogeneity as well as in the variety of powerful approaches to decipher it. Better understanding of the commensal microenvironment and its relation to the now nearly 200 IBD associated genetic loci has added billions of additional variables and revealed many new biologic pathways. Fortunately, analytic methods that find relevant patterns in these massive data sets (big science), along with our ever more precise bench approaches (little science), including specialized in vivo models, stem cell directed human intestinal organoids (HIOs) and sophisticated in vitro technology, render conditioning parameters that can be even further refined by big science approaches. In this proposal, the program project (PPG) is reconfigured to make the best use of both approaches. The interactions and progress over the previous cycle led naturally to an exciting new structure, which takes aim at genetic influences on the host/environmental interface and their individual and combined contributions to severe IBD phenotypes. Our plan is to leverage the PPG's collective experience in multidirectional translation and merge our strengths in big and little science to define the relationship between genetic variation of the host and the commensal microenvironment and the consequential processes leading to severe forms of IBD. We hypothesize that distinguishing signatures of subtypes of severe IBD can be compiled based on an aggregate of genetic variation(s) and resultant gene expression profiles in single or interacting host pathobiologic pathways, in conjunction with metabotypic evidence reflecting alterations in metagenomic relationships between bacterial and/or fungal members of the commensal microenvironment. Elucidating the mechanism(s) of this biologic interface will require purposeful integration of big and little science. The 4 projects and two cores are conceived to approach this hypothesis as follows: Project 1 (McGovern) will generate innovative gene risk scores (GRS), then using a refined big science methodology will define the roles of multiple genes in specific pathways related to severe forms of IBD and to understand their interactions with components of the commensal microenvironment. Project 2 (Targan), deploying little science techniques, including a very novel approach using genotype-specific HIOs, addresses the relationship between TL1A and the microbiome, their individual and combined effects on Paneth cells, and how this interplay contributes to disease severity. Project 3 (Kronenberg), will examine the relationship of the Lt?R network (including TNFAF14/LIGHT) and its relationship to the intestinal microbiome in influencing mucosal inflammation. Project 4 (Underhill), will investigate the relationship between fungal communities and the immune system and their combined contribution to IBD. The engine that drives all of this research is the unique, large repository of samples and correlate genetic, tissue expression, serologic, immunologic and clinical metadata provided by Core B.

Public Health Relevance

Genetic and Immunopathologic Mechanisms Inflammatory Bowel Diseases (IBD) inclusive of Crohn's disease and ulcerative colitis, affect as may as one million Americans. This program attempts to determine, the genetic, environmental and biologic interactions that contribute to severe forms of IBD. The result of these studies could be the identification of new opportunities for the development of improved treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK046763-24
Application #
9074358
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (J3)P)
Program Officer
Karp, Robert W
Project Start
1997-09-30
Project End
2021-07-31
Budget Start
2016-09-02
Budget End
2017-07-31
Support Year
24
Fiscal Year
2016
Total Cost
$2,246,141
Indirect Cost
$780,371
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Weiser, Matthew; Simon, Jeremy M; Kochar, Bharati et al. (2018) Molecular classification of Crohn's disease reveals two clinically relevant subtypes. Gut 67:36-42
Seo, Goo-Young; Shui, Jr-Wen; Takahashi, Daisuke et al. (2018) LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection. Cell Host Microbe 24:249-260.e4
Clerc, Florent; Novokmet, Mislav; Dotz, Viktoria et al. (2018) Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. Gastroenterology 155:829-843
Rivas, Manuel A; Avila, Brandon E; Koskela, Jukka et al. (2018) Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet 14:e1007329
Hong, Myunghee; Ye, Byong Duk; Yang, Suk-Kyun et al. (2018) Immunochip Meta-Analysis of Inflammatory Bowel Disease Identifies Three Novel Loci and Four Novel Associations in Previously Reported Loci. J Crohns Colitis 12:730-741
Freise, Amanda C; Zettlitz, Kirstin A; Salazar, Felix B et al. (2018) Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis. J Nucl Med 59:980-985
Šimurina, Mirna; de Haan, Noortje; Vu?kovi?, Frano et al. (2018) Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology 154:1320-1333.e10
Leonardi, Irina; Li, Xin; Semon, Alexa et al. (2018) CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi. Science 359:232-236
Hui, Ken Y; Fernandez-Hernandez, Heriberto; Hu, Jianzhong et al. (2018) Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med 10:
Schwerd, T; Bryant, R V; Pandey, S et al. (2018) NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunol 11:562-574

Showing the most recent 10 out of 277 publications